DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 990 filers reported holding DANAHER CORPORATION in Q3 2015. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,442,777 | +0.5% | 42,091 | -2.8% | 1.24% | +14.5% |
| Q2 2023 | $10,392,480 | -3.8% | 43,302 | +1.0% | 1.08% | -8.8% |
| Q1 2023 | $10,806,719 | -5.1% | 42,877 | -0.1% | 1.19% | -3.7% |
| Q4 2022 | $11,388,641 | +2.6% | 42,908 | -0.1% | 1.23% | -1.9% |
| Q3 2022 | $11,096,000 | +2.6% | 42,959 | +0.7% | 1.26% | +13.6% |
| Q2 2022 | $10,820,000 | -12.8% | 42,679 | +0.9% | 1.11% | +2.5% |
| Q1 2022 | $12,403,000 | -19.6% | 42,282 | -9.9% | 1.08% | -19.3% |
| Q4 2021 | $15,435,000 | +7.4% | 46,913 | -0.6% | 1.34% | +3.2% |
| Q3 2021 | $14,371,000 | +10.4% | 47,206 | -2.7% | 1.30% | +12.9% |
| Q2 2021 | $13,014,000 | +19.4% | 48,494 | +0.2% | 1.15% | +9.6% |
| Q1 2021 | $10,898,000 | +4.7% | 48,419 | +3.3% | 1.05% | -3.4% |
| Q4 2020 | $10,408,000 | +3.0% | 46,854 | -0.1% | 1.08% | -12.5% |
| Q3 2020 | $10,102,000 | +23.4% | 46,914 | +1.3% | 1.24% | +1.5% |
| Q2 2020 | $8,187,000 | +28.1% | 46,302 | +0.3% | 1.22% | +28.3% |
| Q1 2020 | $6,392,000 | -12.2% | 46,184 | -2.6% | 0.95% | +15.4% |
| Q4 2019 | $7,278,000 | +5.1% | 47,423 | -1.1% | 0.82% | +1.6% |
| Q3 2019 | $6,923,000 | +0.7% | 47,934 | -0.4% | 0.81% | -0.2% |
| Q2 2019 | $6,877,000 | -5.8% | 48,118 | -13.0% | 0.81% | -8.8% |
| Q1 2019 | $7,303,000 | +22.5% | 55,315 | -4.3% | 0.89% | +10.0% |
| Q4 2018 | $5,962,000 | -3.6% | 57,808 | +1.5% | 0.81% | +20.3% |
| Q3 2018 | $6,186,000 | +6.6% | 56,927 | -3.2% | 0.68% | +4.3% |
| Q2 2018 | $5,803,000 | +5.0% | 58,801 | +4.2% | 0.65% | +0.3% |
| Q1 2018 | $5,527,000 | +12.1% | 56,447 | +6.3% | 0.64% | +20.8% |
| Q4 2017 | $4,929,000 | +71.4% | 53,097 | +58.4% | 0.53% | +75.7% |
| Q3 2017 | $2,876,000 | +171.6% | 33,528 | +167.2% | 0.30% | +151.2% |
| Q2 2017 | $1,059,000 | -11.4% | 12,550 | -10.2% | 0.12% | -10.4% |
| Q1 2017 | $1,195,000 | +9.4% | 13,975 | -0.4% | 0.14% | +8.0% |
| Q4 2016 | $1,092,000 | -0.6% | 14,025 | 0.0% | 0.12% | -4.6% |
| Q3 2016 | $1,099,000 | -22.4% | 14,025 | 0.0% | 0.13% | -29.6% |
| Q2 2016 | $1,417,000 | -25.9% | 14,025 | -30.4% | 0.19% | -28.5% |
| Q1 2016 | $1,912,000 | -28.7% | 20,152 | -30.2% | 0.26% | -35.5% |
| Q4 2015 | $2,682,000 | -45.2% | 28,882 | -49.7% | 0.40% | +18.5% |
| Q3 2015 | $4,898,000 | +259.4% | 57,474 | +266.0% | 0.34% | +96.5% |
| Q2 2015 | $1,363,000 | +30.3% | 15,703 | +27.5% | 0.17% | +28.1% |
| Q1 2015 | $1,046,000 | +386.5% | 12,314 | +335.1% | 0.14% | +440.0% |
| Q3 2014 | $215,000 | – | 2,830 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |